Quanterix (NASDAQ:QTRX) Releases Earnings Results, Beats Expectations By $0.16 EPS

Quanterix (NASDAQ:QTRX) released its quarterly earnings data on Monday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.16, Zacks reports. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Quanterix updated its FY 2025 guidance to EPS.

Quanterix Price Performance

QTRX stock traded up $0.45 during midday trading on Monday, reaching $5.73. 529,934 shares of the stock were exchanged, compared to its average volume of 780,423. The company has a fifty day moving average price of $6.15 and a 200 day moving average price of $9.06. Quanterix has a 52 week low of $4.67 and a 52 week high of $19.17. The stock has a market capitalization of $222.26 million, a PE ratio of -5.41 and a beta of 1.12.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on QTRX shares. Leerink Partners reissued a “market perform” rating and issued a $8.00 target price (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Scotiabank reaffirmed an “outperform” rating on shares of Quanterix in a research report on Tuesday, March 25th. Canaccord Genuity Group decreased their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Finally, Leerink Partnrs downgraded Quanterix from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Quanterix presently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.